Ipsen's Stock Falls 2%, Market Awaits Four Phase III Readouts
This Wednesday morning, the biopharmaceutical laboratory shows a significant decline, going against the grain of a well-oriented Parisian market. The stock erases part of its recent rebound and falls below its short-term moving averages, while the clinical pipeline remains active with several catalysts expected this summer.
The stock falls below its short-term moving averages but retains 54% year-on-year
Ipsen's stock loses 2.11% to €158.00, among the sharpest declines in the SBF 120, while the broader index gains 0.50% during the session. The stock is now trading below the MM20 at €164.11 (a gap of -3.72%) and below the MM50 at €161.27 (-2.03%), confirming the slowdown that began after last week's technical rebound. However, the underlying trend remains strong: the MM200 at €135.72 is significantly below the current price (+16.42% gap) and the performance is +53.85% year-on-year. The RSI at 48 remains neutral, without a marked directional signal. The support at €154.90 is the next technical reference, 2% below current levels.
A dense pipeline with four Phase III readouts expected by the end of August
The laboratory continues to hit clinical milestones. On May 19, the group published the results of the DIRECTION study, which demonstrated the non-inferiority of Dysport compared to Botox in upper limb spasticity, the first direct double-blind comparison between the two toxins. The schedule for the coming weeks remains busy, with two Phase III readouts on Dysport for chronic migraine expected on July 20 and for episodic migraine on July 26, followed by two more Phase III readings on Elafibranor in primary biliary cholangitis and on Odevixibat in biliary atresia at the end of August. Regarding governance, Karen Witts left the board of directors following the AGM on May 13, with Pascal Touchon serving as the interim audit committee. The density of the clinical calendar over the next three months will be the main fundamental reference for the stock.
